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SUMMARY 
NUT carcinoma (NC) represents a rare subset of highly aggressive poorly differentiated 
carcinomas characterized by rearrangement of the NUT (aka NUTM1, nuclear protein in 
testis) gene, most commonly fused to BRD4. Originally described as a 
mediastinal/thymic malignancy, NC has been reported at a variety of anatomic regions 
including the upper and lower aerodigestive tract. To date, only seven NC cases of 
probable salivary gland origin have been reported. We herein describe three new cases 
(all affecting the parotid gland) in two women (39 and 55 years old) and one man (35-
years old). Histological examination showed poorly differentiated neoplasms composed 
of poorly cohesive small to medium-sized cells with variable squamoid cell component 
that was focal and abrupt. Immunohistochemistry showed uniform expression of p63 
and distinctive punctate expression of the NUT antigen in the tumor cell nuclei. Review 
of the reported salivary gland NC cases (total: 10) showed a male: female ratio of 1.5:1 
and an age range of 12 to 55 years (median: 29). Site of the primary tumor was the 
parotid (7), sublingual (2) and submandibular (1) glands. All presented as rapidly 
growing masses treated by surgery followed by adjuvant radio-/chemotherapy. Initial 
nodal status was positive in 8/10. At last follow-up (1 to 24 months; median: 5), 7/10 
patients died of disease at a median of 5.5 months (1-24 months). Of 9 cases with genetic 
data, the fusion partner was BRD4 (n=7), non-BRD4/3 (n=1) or undetermined (n=1). 
None of 306 salivary gland carcinomas spanning the spectrum of salivary carcinoma 
types screened by NUT IHC was positive. This is the first small series on salivary NC 
highlighting the importance to include this rare disease in the differential diagnosis of 
poorly differentiated salivary gland carcinomas and in cases of presumable poorly 
differentiated carcinoma of unknown origin.  
Key words: salivary glands; carcinoma; NUT carcinoma; midline carcinoma; poorly 
differentiated carcinoma; squamous cell carcinoma; BRD4; FISH. 
INTRODUCTION 
 
NUT carcinoma (NC) represents a rare subset of highly aggressive poorly differentiated 
epithelial neoplasms defined by rearrangement of the NUT gene, which is most 
commonly fused to BRD4 to form the BRD4-NUT oncogene.1 Originally described in 1991 
as a mediastinal/thymic malignancy2, NC has been recently reported from a variety of 
anatomic regions including in particular the upper and lower aerodigestive tract, but 
rarely  intra-abdominal organs as well.3-7 Affected patients are mainly young adults but 
the age range varies greatly from the new-born to the elderly.3-7 Although originally 
considered strictly a neoplasm related to midline structures, recent case reports 
described this rare disease in lateralized organs such as the lungs and parotid gland. For 
this reason, the World Health Organization (WHO) classification of tumors has changed 
the name from NUT midline carcinoma to NUT carcinoma.8-10 A thorough review of the 
English literature uncovered a total of 7 single case reports of NC of probable or possible 
salivary gland origin.11-17 We herein describe three new NC cases originating in the 
parotid gland and review previously reported cases. 
 
MATERIALS AND METHODS 
The three NC cases were retrieved from the consultation files of three of the authors 
(A.A., I.F. and C.F.). They have been diagnosed in the years 2010, 2015 and 2017. 
Immunohistochemistry (IHC) was performed on 3-µm sections cut from paraffin blocks 
using a fully automated system (“Benchmark XT System”, Ventana Medical Systems Inc, 
1910 Innovation Park Drive, Tucson, Arizona, USA) and the following antibodies: 
pankeratin (clone AE1/AE3, 1:40, Zytomed, Berlin, Germany), CK7 (OV-TL, 1:1000, 
Biogenex), p63 (SSI6, 1: 100, DCS), S100 protein (polyclonal, 1:2500, Dako), CD56 (clone 
MRQ-42, 1:100, CELL MARQUE), chromogranin A (clone LK2H10, 1:500, Beckman-
Coulter GmbH), synaptophysin (clone SY38, 1:50, Dako), SMARCB1 (MRQ-27, 1:50, 
Zytomed), and anti-NUT antibody (clone C52B1, 1:45, Cell Signaling). Interpretation of 
results of the NUT IHC was based on published data showing distinctive granular 
(punctate or dusty) nuclear immunoreactivity present in > 50% of neoplastic cell 
nuclei.18 Epstein Barr virus (EBV) in-situ hybridization (EBER 1/2 probes, ZytoVision, 
Bremerhaven, Germany) was performed according to the manufacturer guidelines. 
Positive and negative controls were used throughout. Normal testicular tissue was used 
as a positive control for the NUT IHC.5,6 
 
FISH 
To detect gene translocation involving the NUT gene locus, FISH was performed on 
sections cut from formalin-fixed paraffin-embedded tissue blocks using the ZytoLight 
SPEC NUT Dual Color Break Apart Probe (ZytoVision, Bremerhaven, Germany) with 
standard protocols according to the manufacturer`s instructions. The presence of two 
pairs of fused green and orange signals was considered normal findings. On the other 
hand, translocation-positive nuclei showed one fused orange/green signal and one 
separate orange and green signal. 200 nuclei were counted in four different areas of 
each tumor. Eighty percent positive interpretable nuclei were defined as positive for a 
rearrangement. 
To identify the BRD4-NUT chromosomal translocation by FISH, BRD4 and NUT dual color 
split-apart FISH on formalin-fixed, paraffin embedded sections was performed as 
described4, using the following probes for NUT split-apart: NUT 5' centromeric probes, 
RP11-368L15 and RP11-1084A12 (biotin labeled, red) and NUT 3’ telomeric probes, 
RP11-1H8 and RP11-64o3 (digoxigenin labeled, green); and the following probes for 
BRD4 split-apart: BRD4 5’ centromeric probes, RP11-207i16 and RP11-3055m5 (biotin 
labeled, red), and BRD4 3' telomeric probes, RP11-319O10 and RP11-681D10 
(digoxigenin labeled, green). 
Case 3 was in addition evaluated by conventional karyotyping studies. Chromosome 
metaphases of tumor cells were obtained from short term primary cultures as 
previously described.19 Chromosomes were GTG-banded, and the karyotype was 
established according to the ISCN rules (2016).  
 
Immunohistochemical screening for NUT expression in salivary gland carcinomas 
A total of 306 salivary gland carcinomas were stained with the monoclonal anti-NUT 
antibody (281 using tissue microarrays and the remainder on conventional slides). 
Histological subtypes according to the most recent WHO classification20 were 
summarized in table 1. 
 
RESULTS 
Clinical history  
Case 1 
A 39 year-old female without significant past medical or family history presented with a 
rapidly enlarging, infiltrative tumor of the right parotid gland and right-sided 
lymphadenopathy, which was excised by radical parotidectomy and right levels II-III 
neck dissection at her local hospital. This was diagnosed locally as likely high-grade 
mucoepidermoid carcinoma. The patient underwent adjuvant chemoradiotherapy (66Gy 
33# with weekly cisplatin). Approximately three months after excision, imaging showed 
disseminated metastatic disease to the bone (to sacrum, third lumbar vertebra, left neck 
of femur and rib), lymph nodes and lungs. She went on to receive palliative radiotherapy 
to the lumbosacral spine (30 Gy 10#). She was referred to our center to discuss further 
potential treatment options. Pathology review showed NUT carcinoma. The patient was 
given palliative radiotherapy, and three months later commenced on an investigational 
targeted therapy, but died of progressive disease four months after this.   
 
Case 2 
A 35-year-old man underwent total parotidectomy and neck dissection for an infiltrative 
parotid mass. Histological evaluation (performed abroad) was reported as 
undifferentiated large cell carcinoma of the parotid corresponding to pT3 pN2b, grade 3, 
R0. Postoperative investigations (three months later) showed multiple osseous 
metastases. A biopsy was obtained from the pelvic bone. The initial blocks/slides could 
not be retrieved for review. Palliative chemotherapy was initiated. 
Case 3 
A 55-year-old female noted a right parotid mass that rapidly grows to a size of 9 cm in 
greatest dimension. She underwent superficial parotidectomy in another institution. 
Three months later, she presented with a recurrence at the parotidectomy scar and 
underwent total parotidectomy with facial nerve excision and a radical neck dissection 
(at this time a pT3pN1) complemented with chemo- and radiotherapy. Six months after 
initial diagnosis, she developed lung, liver and bone metastasis and died of her 
progressive disease seven months after primary surgery.  
 
Pathological findings 
Pathological features were essentially comparable and are described herein together. All 
tumors were located within the salivary gland parenchyma (Fig. 1A). They were 
disposed in cords, nests and/or diffuse poorly cohesive sheets of undifferentiated but 
relatively uniform small to medium-sized polygonal cells (Fig. 1B-E). The tumor cell 
nuclei showed variable chromatin condensation with inconspicuous (Fig. 1C) to variably 
recognizable nucleoli (Fig. 1F) and were surrounded by a moderate rim of pale-
eosinophilic to clear cytoplasm. Superficial resemblance to poorly differentiated 
squamous cell carcinoma was most evident in Case 1 (Fig. 1D, E). The latter showed 
acutely inflamed stroma with prominent stromal and intraepithelial granulocytosis (Fig. 
1F). Prominent single cell necrosis/apoptosis and extensive areas of necrosis were 
frequent. Islands of abrupt squamous differentiation were noted in all three cases 
including the bone metastasis from case 2 (Fig. 2A, B). The background stroma varied 
from edematous slightly myxoid to fibrous. Entrapment of native ductules was a 
prominent feature in all cases (Fig. 2A, C), occasionally with entrapment of single goblet 
cells, likely of ductal origin (Fig. 2A). Other unusual features included variable 
myxohyaline stromal changes with entrapped basaloid neoplastic nests that might be 
mistaken for preexisting pleomorphic or basal cell adenoma (Fig. 2D).   
Immunohistochemistry showed uniform expression of p63 (Fig. 3A), variable reactivity 
for pancytokeratin and lack of neuroendocrine marker expression. In areas lacking 
strong pancytokeratin expression, the latter highlighted the foci of abrupt squamous 
differentiation. All three tumors showed distinctive punctate nuclear expression of the 
NUT protein (Fig. 3B, C). EBER ISH was negative in all cases. 
 
FISH analysis using the NUT probe showed break apart signals in >90% of the neoplastic 
cell nuclei in all three cases (Fig. 3D). BRD4 was the fusion partner in case 1 (determined 
by FISH (Fig. 3E) and Case 3 (conventional karyotyping studies revealed a 43~46, XX, 
t(15;19)(q14;p13) karyotype corresponding to a NUT/BRD4 translocation). In Case 3, 
the fusion partner could not be determined due failure of FISH testing as a result of poor 
tissue preservation. 
NUT IHC in unselected salivary gland carcinoma types 
None of 306 salivary gland carcinomas across the spectrum of salivary carcinoma types 
screened with the NUT IHC was positive (table 1). 
 
Clinicopathologic features of all known salivary NCs 
Including our three cases, a total of 10 salivary NC cases have been reported (table 2).11-
17 They affected mainly males (M: F ratio = 1.5: 1) with an age range of 12 to 55 years 
(median: 29). Nine patients were under 40 years at the time of diagnosis and 3/10 cases 
were children. Site of origin of the primary tumor was the parotid (n=7), the sublingual 
(n=2) and the submandibular (n=1) glands. Regarding laterality, six tumors were on the 
right and three on the left side (one of unknown laterality). All tumors presented as 
rapidly growing masses. Regional lymph nodes were initially involved in 8/10 cases. 
Treatment was surgery followed by adjuvant radio-/chemotherapy in all cases. The 
majority of patients developed rapid postoperative disseminated disease. At last follow-
up (1 to 24 months; median: 5), 6/10 patients died of disease at a median of 5.5 months 
(1-24 months). One patient was alive with metastatic disease under palliative treatment 
while only two patients were alive without evidence of disease at 7 and 14 months.  
All eight tumors stained with the anti-NUT antibody showed positive nuclear staining 
and all 9 cases assessed by genetic methods (FISH and/or karyotyping) showed NUT 
rearrangement. The fusion partner was BRD4 (n=7), non-BRD4/3 (n=1) or unknown due 
to FISH failure (n=1). As illustrated in table 3, NC of salivary glands showed frequent 
expression of pancytokeratin (8 of 9 cases) and consistently expressed p63 (9 of 9 cases) 
similar to their non-salivary counterparts.4,5 Neuroendocrine markers were largely 
negative except for focal minor expression of synaptophysin (2 of 9 cases) and variable 
reactivity for CD56 (2 of 9 cases) observed in two cases each, respectively. All cases have 
been consistently negative for EBV ISH. Our cases were stained with SMARCB1; all three 
showed intact expression. The original diagnosis was stated in 9 cases. A diagnosis of 
undifferentiated or poorly differentiated SCC/carcinoma/tumor was rendered or 
suggested in 6 cases. The remaining three cases were interpreted as probably 
representing high-grade variants of myoepithelial carcinoma, adenoid cystic carcinoma 
or mucoepidermoid carcinoma.  
 
DISCUSSION 
Since its first description as a mediastinal (midline) malignancy2, NC has been reported 
from diverse sites with about one third-to-one half of cases originating in the head and 
neck area.3,5,6 More than half of head and neck cases affected the sinonasal cavities.5,6 
While this rare disease probably is still significantly under-recognized, even at these 
characteristic (mediastinal and sinonasal) sites, NC originating at unusual sites such as 
the salivary glands is likely under-recognized as well. This is mainly due to the 
superficial similarity of this neoplasm to conventional squamous cell carcinoma (SCC) 
and the uniform reactivity for p63 as a marker of squamous cell differentiation. Review 
of the English literature uncovered 7 single case reports describing NC in or closely 
associated with salivary glands.  
 
As reflected in the initial diagnostic suggestions, NC was not considered in the vast 
majority of cases and the diagnosis was mainly made after molecular testing. Thus, this 
carcinoma variant might be more common in the salivary glands than the current 
literature suggests, as diagnosis is only feasible if NC is included in the differential 
diagnosis and NUT IHC performed. Otherwise, a diagnosis of poorly differentiated SCC, 
sebaceous carcinoma or undifferentiated/anaplastic carcinoma unclassified would have 
been rendered, based on the appearance of the neoplasm and presence or absence of 
squamoid areas. 
 The prognosis of NC is poor with the majority of patients succumbing to their disease 
within a few months of diagnosis.21,22 This is mainly the consequence of aggressive 
nature of NC with a high rate of regional and distant disease dissemination usually 
shortly after diagnosis and to the lack of response to conventional chemotherapeutic 
regimens. As a consequence of global transcriptional repression and blockade of cell 
differentiation likely resulting from the underlying genetic aberration, NC frequently 
displays undifferentiated phenotype by conventional histology.23  
Recognition of NC is mandatory for providing important prognostic information specific 
to this entity and is essential for optimizing patient´s therapy. In addition, emerging new 
therapeutic strategies targeting the underlying gene fusion (bromodomain inhibitors 
and histone deacetylase inhibitors) might be a promising option for this orphan disease 
in the future.24,25 Thus recognition of NC is encouraged for a better characterization of 
this lethal disease. 
 
Although NC is considered a variant of SCC by some authors, its relationship to 
conventional SCC is unclear. Lack of other molecular alterations in NC in contrast to the 
highly heterogeneous molecular profile of conventional SCC argues for the BRD-NUT 
fusion being the sole driver of this rare disease.2,3 The frequency of NC among salivary 
gland cancer is unknown. In the sinonasal tract, NC accounted for 10% of poorly 
differentiated/undifferentiated carcinomas.26 Lack of NUT immunoreactivity among 306 
salivary gland carcinomas across the spectrum of salivary carcinoma types screened in 
this study suggests the rarity of NC among consecutive salivary gland carcinomas which 
is in line with the rarity of this entity in other organs as well. However, as NUT 
rearrangements are not expected among specific differentiated subtypes of salivary 
gland carcinomas other than poorly differentiated SCC and undifferentiated carcinomas, 
the exact frequency of NC among poorly differentiated/ undifferentiated primary 
salivary gland carcinomas remains to be assessed in future studies. Thus, it is 
recommended to include NUT IHC in the workup of undifferentiated carcinomas and in 
SCC in the salivary glands with features suggestive of NC as reported above. However, 
blind screening of salivary gland carcinomas that are fitting the well characterized 
carcinoma types seems to be useless. The NUT IHC is considered sufficient for diagnosis 
based on the high specificity (almost 100%) and sensitivity (87%) of the antibody.5,6,18 
While genetic testing is generally not necessary for diagnosis, it is recommended to 
determine the fusion partner for better understanding and characterization of this rare 
aggressive disease. There is preliminary evidence suggesting prognostic difference 
between BRD4-NUT and NUT-variant carcinomas with the latter possibly associated 
with longer overall survival.4 
  
Salivary NUT carcinoma should be distinguished from a variety of primary and 
metastatic neoplasms including poorly differentiated SCC, myoepithelial carcinoma, 
high-grade mucoepidermoid carcinoma, basal cell adenocarcinoma and epithelial 
myoepithelial carcinoma. While most of these salivary gland carcinoma entities can be 
excluded by well-established diagnostic criteria, some secondary morphological features 
entrapment of reactive ducts and distorted native ductal epithelium (including goblet 
cells) might be a source of confusion. It is possible that these entrapped normal tissue 
elements might explain some of the original diagnoses in previously reported cases 
including high-grade mucoepidermoid carcinoma and adenoid cystic carcinoma. 
Furthermore, heterologous cartilaginous differentiation as reported in a previous 
salivary NC should be distinguished from carcinoma ex pleomorphic adenoma.11 
Likewise, presence of cells with voluminous clear cytoplasm (abrupt squamous 
differentiation) should not be mistaken for sebaceous differentiation. Based on these 
differential diagnostic considerations and given the heterogeneous and non-specific 
NUT carcinoma morphology, inclusion of NUT carcinoma in the differential diagnosis 
and use of the NUT immunohistochemistry in the work-up of unclassified or atypical 
looking carcinomas is encouraged. 
In summary, this is the first small series on salivary NC highlighting the importance to 
include this rare disease in the differential diagnosis of poorly differentiated salivary 
gland carcinomas, in particular in cases of poorly differentiated SCC of presumable 
salivary gland origin or of unknown origin and in high-grade myoepithelial carcinomas.  
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Table 1: Summary of the salivary gland tumors tested for NUT immunoexpression in this 
study 
Tumor type +/Total number of cases tested 
Adenoid cystic carcinoma (7 high-grade) 0/50 
Mucoepidermoid carcinoma 0/41 
Salivary duct carcinoma* 0/62 
high-grade adenocarcinoma/NOS* 0/35 
Acinic cell carcinoma 0/32 
Poorly differentiated SCC** 0/28 
Myoepithelial carcinoma 0/17 
polymorphous carcinoma*** 0/13 
Undifferentiated/rhabdoid carcinoma 0/05 
Basal cell adenocarcinoma 0/07 
Oncocytic carcinoma 0/04 
Epithelial myoepithelial carcinoma 0/04 
Primary malignant mixed tumor 0/04 
Poorly differentiated neuroendocrine 
carcinoma 
0/02 
Cystadenocarcinoma 0/02 
Total 0/306 
*= this group includes also some carcinoma ex pleomorphic adenoma cases. 
**= this group includes tumors without detectable other primary at time of clinical workup 
but many likely represent metastases from others, e.g. previous skin carcinomas, occult 
primaries, etc..  
***=all cases belong to the old category of polymorphous low-grade adenocarcinoma 
(PLGA). 
Table 2: Clinicopathologic Features of Reported NUT Carcinomas of the Salivary Glands 
(n=10) 
 
 
Table 3: Histopathological, immunohistochemical and molecular findings in salivary NUT carcinomas (n=10). 
Case  Histological pattern unusual 
features 
Original 
diagnosis 
Pan-CK p63 CK7 SYN Ch-A CD56 INI1 NUT IHC Genotype 
1 Poorly cohesive 
basaloid cells, 
squamoid islands 
Foci of 
cartilage 
Poorly 
differentiated 
carcinoma (FNA) 
+ + NA - - + NA + NUT-BRD4 
2 Poorly cohesive 
basaloid cells, 
squamoid islands 
No Nots specified + + NA - - - NA NA NUT-variant (other than 
BRD4/BRD3) 
3 Basaloid with 
desmoplasia, no 
squamous islands 
No Poorly 
differentiated 
SCC 
+ + NA - - - NA + NA 
4 Poorly cohesive large 
cells 
No Myoepithelial 
carcinoma with 
neuroendocrine 
features 
+ + NA +F NA + NA + NUT-BRD4 
5 Poorly cohesive 
basaloid cells, 
squamoid islands 
No Poorly 
differentiated 
basaloid SCC 
+ + + <1% - - NA + NUT-BRD4 
6 Poorly cohesive 
basaloid cells 
No Poorly 
differentiated 
AdCC (FNA) 
+ + NA - - - NA + NUT-BRD4 
7 Poorly cohesive large 
cells 
No Undifferentiated 
carcinoma 
NA NA NA NA NA NA NA NA NUT-BRD4 
8 
 
Poorly cohesive large 
cells, squamoid 
islands 
Prominent 
granulocytes  
High-grade 
tumor, favor MEC 
+ + + - - - intact  + NUT-BRD4 
9 
 
Poorly cohesive 
basaloid cells, 
squamoid islands 
No Undifferentiated 
large cell 
carcinoma 
+ + NA - - - intact + NUT, partner unknown 
(FISH failed) 
10 
 
Poorly cohesive 
basaloid cells, 
squamoid islands 
No Undifferentiated 
tumor 
- + - - - - intact + NUT-BRD4 
AdCC, adenoid cystic carcinoma; Pan-CK, pancytokeratin; Ch-A, chromogranin A; FNA, fine needle aspiration; F, focal; IHC, immunohistochemistry; NA, not available; 
MEC, mucoepidermoid carcinoma; SSC, squamous cell carcinoma; SYN, synaptophysin. 
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Figure 1. Salivary NCs were centered within salivary parenchyma (A) and displayed poorly cohesive sheets of small-sized to 
medium-sized cells arranged into pseudoalveolar (B), solid (C), corded (D), or nested (E) pattern. The nucleoli ranged from 
inconspicuous (C) to prominent (F), note extensive granulocytosis in F (A, B, C from case 3; D, E, F from case 1). 
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Figure 2. Foci of abrupt (clear cell) keratinization were seen in all 3 cases. Potentially 
misleading features included florid ductular proliferations (A, C) with entrapped of rare goblet 
cells (A, midlower field) and myxohyaline stromal changes reminiscent of pleomorphic 
adenoma (D). A to D from case 3. 
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Figure 3. IHC showed consistent expression of p63 (A, case 3) and NUT protein (B, case 2). 
The NUT immunostain highlighted the neoplastic cells amid native salivary tissue (C, case 3). 
FISH analysis using the NUT probe (D) and BRD4 probe (E) showed break-apart  signals  
indicating a NUT/BRD4 translocation (image from case 1) 
 
 
